Applied DNA Sciences receives Nasdaq delisting notice for bid price deficiency; requests hearing

BNB PLUS CORP.

Nasdaq notified APDN on May 30, 2025 that bid price closed below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).
APDN executed a 1-for-15 reverse stock split on June 2, 2025 to address deficiency, but is ineligible for a compliance period due to prior reverse splits.
Company timely requested a hearing before Nasdaq Hearings Panel on June 6, 2025, which stays any suspension or delisting pending outcome.
No assurance that the Panel will grant continued listing; shares remain at risk of delisting.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.